The expression pattern of contractile and intermediate filament proteins in developing skeletal muscle and rhabdomyosarcoma of childhood: diagnostic and prognostic utility.
In order to investigate whether rhabdomyosarcoma (RMS) can be related to equivalent stages of skeletal muscle development, muscle tissue of 21 human foetuses and 112 primary RMSs were characterized immunohistochemically using antibodies directed against vimentin, desmin, muscle-specific actin (HHF35), sarcomeric actin (sr-actin), smooth muscle actin (sm-actin), and troponin-T. During fetal skeletal muscle development, all myotubes/fibres of the first and second generations expressed desmin, HHF35, and sr-actin. Vimentin was almost exclusively present in immature primary and secondary myotubes/fibres. Troponin-T was expressed in immature myotubes/fibres of the first and second generations as well as mature fibres of the second generation. Sm-actin was never expressed. Vimentin was expressed in 96 per cent of primary and 98 per cent of relapsed RMS; HHF35 in 96 and 98 per cent, respectively; desmin in 95 and 100 per cent; troponin-T in 82 and 75 per cent; sr-actin in 71 and 86 per cent; and sm-actin in 13 and 17 per cent. The proportion of RMS cells reacting with vimentin, HHF35, and desmin was consistently higher than those expressing sr-actin and troponin-T. Neither the shape nor size of neoplastic RMS cells nor the histopathological types were related to the expression pattern of the investigated markers. RMS with aberrant expression of two or more markers predicted a worse prognosis than RMS in which at most one marker was aberrantly expressed (25 per cent and 54 per cent 10-year survival, P = 0.01). These results demonstrate that HHF35, desmin, sr-actin, and troponin-T have the potential to confirm the commitment of the tumours to the myogenic pathway which supports the diagnosis of RMS. However, it was impossible to relate RMS to equivalent stages of skeletal muscle development. Aberrant marker expression by RMS cells correlated significantly with patients' survival.
Wijnaendts
L C
LC
Department of Pathology, Free University of Amsterdam, The Netherlands.
van der Linden
J C
JC
van Unnik
A J
AJ
Delemarre
J F
JF
Voute
P A
PA
Meijer
C J
CJ
D000199:Actins / Q000032:analysis; D000293:Adolescent; D000328:Adult; D015415:Biomarkers / Q000032:analysis; D002648:Child; D002675:Child, Preschool; D003285:Contractile Proteins / Q000032:analysis*; D003893:Desmin / Q000032:analysis; D005260:Female; D006258:Head and Neck Neoplasms / Q000737:chemistry* / Q000175:diagnosis; D006801:Humans; D007150:Immunohistochemistry; D007223:Infant; D007381:Intermediate Filament Proteins / Q000032:analysis*; D008297:Male; D018482:Muscle, Skeletal / Q000737:chemistry / Q000196:embryology*; D011379:Prognosis; D012208:Rhabdomyosarcoma / Q000737:chemistry* / Q000175:diagnosis; D014336:Troponin / Q000032:analysis; D020107:Troponin T; D014565:Urogenital Neoplasms / Q000737:chemistry / Q000175:diagnosis; D014746:Vimentin / Q000032:analysis
D000199:Actins; D015415:Biomarkers; D003285:Contractile Proteins; D003893:Desmin; D007381:Intermediate Filament Proteins; D014336:Troponin; D020107:Troponin T; D014746:Vimentin